Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer.
brachytherapy
iodine-125
prostate cancer
quality of life
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
26
03
2020
accepted:
21
09
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
ppublish
Résumé
This prospective longitudinal study quantifies health-related quality of life (HRQoL) up to 10 years following permanent iodine-125 ( In total, 120 patients completed a validated expanded prostate cancer index composite (EPIC) questionnaire pre-treatment and at 8 time points after treatment (6 weeks, 6, 10, 18 months, and 2, 3, 5, 10 years). At each time point, clinically relevant small, moderate, and severe declines in HRQoL were defined as 0.2-0.5 SD, 0.5-0.8 SD, and > 0.8 SD of baseline function for each of urinary, bowel, and sexual domains, respectively. Response rates in the first two years were > 90%, but thereafter dropped to 75% and 48% at 5 and 10 years, respectively. 50 patients (41.6%) responded at all stages. Maximal deterioration in mean urinary and sexual summary scores was noted 6 weeks after implant, with severe urinary symptoms and moderate bowel/sexual symptoms. At 6 months, urinary and bowel quality of life (QoL) had improved to mild impairment, which then fully resolved at 10 months. Sexual QoL remained mildly impaired throughout the 10 years of follow-up. At 10 years, new mild impairment of urinary and bowel QoL was found. Clinically mild changes in urinary, bowel, and sexual QoL are found 10 years after
Identifiants
pubmed: 33437301
doi: 10.5114/jcb.2020.101686
pii: 42675
pmc: PMC7787209
doi:
Types de publication
Journal Article
Langues
eng
Pagination
540-546Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Urology. 2010 Nov;76(5):1150-6
pubmed: 20869105
J Clin Oncol. 2009 Aug 20;27(24):3916-22
pubmed: 19620493
Urology. 2015 Jan;85(1):101-5
pubmed: 25530370
Radiother Oncol. 2007 Aug;84(2):135-9
pubmed: 17604140
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Brachytherapy. 2015 Mar-Apr;14(2):148-59
pubmed: 25516492
Int J Impot Res. 2007 Sep-Oct;19(5):448-57
pubmed: 17554396
JAMA. 2020 Jan 14;323(2):149-163
pubmed: 31935027
Eur Urol. 2017 Dec;72(6):869-885
pubmed: 28757301
J Urol. 2011 May;185(5):1674-80
pubmed: 21419449
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):570-8
pubmed: 25151536
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Brachytherapy. 2009 Apr-Jun;8(2):197-206
pubmed: 19433321
J Clin Oncol. 2011 Feb 1;29(4):362-8
pubmed: 21149658
World J Urol. 2009 Oct;27(5):607-12
pubmed: 19455340
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1072-9
pubmed: 20615621
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):50-6
pubmed: 20005453
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1054-60
pubmed: 20097486
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
Radiother Oncol. 2004 Oct;73(1):33-8
pubmed: 15465143
Brachytherapy. 2007 Jul-Sep;6(3):173-9
pubmed: 17681239
J Clin Oncol. 2010 Nov 1;28(31):4687-96
pubmed: 20921463
Radiother Oncol. 2000 Dec;57(3):315-21
pubmed: 11104892